DEALS: Roche, Actelion ink $630M pact

DEALS

WHO

WITH

WHAT

SCOOP

Roche

Actelion

$630M deal

Roche and Actelion will team up to develop and market S1P1, an autoimmune disorder drug.

Archemix

Elan

$350M deal

Archemix will develop up to three aptamer-based drugs for autoimmune inflammatory disease during the three-year pact.

Johnson & Johnson

MGI Pharma

$80M licensing deal

J&J is licensing Dacogen, which was approved by the FDA last May for patients with myelodysplastic syndromes.

CSL Limited

Zenyth Therapeutics

$108M buyout

CSL will acquire 100 percent of the issued shares in Zenyth.

Johnson & Johnson

Colbar LifeScience

$50M buyout

Colbar LifeScience specializes in reconstructive medicine and tissue engineering.

Dava Pharmaceuticals

Stada Arzneimittel

$40M buyout

Stada Arzneimittel will sell its U.S. generics subsidiary to Dava Pharmaceuticals for $40 million and exit the market entirely.

Procter & Gamble

Aryx Therapeutics

$25M licensing deal

The deal is for Aryx's gastrointestinal disorder drug. A successful commercial launch will add up to $435M to the deal

Ranbaxy Laboratories

GSK's Mundogen

Buyout

The acquisition is part of Ranbaxy's strategy to bolster its presence in the European markets.

Locus Pharmaceuticals

Ono Pharmaceutical

Drug discovery pact

Locus has inked a drug discovery deal to target a protein kinase molecule selected by Ono.

Athenagen

Zapaq

Merger

Athenagen and Zapaq both have drug compounds aimed at Alzheimer's disease in their pipelines.

Cardiome

Astellas

Development deal

Cardiome and Astellas have revised their development pact on RSD 1235, an experimental therapy for atrial fibrillation.

Takeda

Galaxy Biotech

Drug license pact

The licensing pact will allow Takeda to develop, manufacture and sell Galaxy's monoclonal antibody for cancer treatment.

Schering

Avid Radiopharmaceuticals

Development deal

Schering has signed an agreement with Avid Inc to develop new diagnostic imaging agents for Alzheimer's disease.